<DOC>
	<DOCNO>NCT02064374</DOCNO>
	<brief_summary>This study phase 1 , open label , parallel group , three period crossover study evaluate effect dolutegravir ( DTG ) steady state pharmacokinetics metformin safety tolerability dolutegravir metformin . Subjects screen visit within 30 day prior first dose study drug , three treatment period , follow visit 7-14 day last dose study drug . Eligible subject assign one two treatment cohort . Subjects receive metformin 500 milligram ( mg ) every 12 hour ( q12h ) 5 day Period 1 ; metformin 500 mg q12h plus dolutegravir 50 mg every 24 hour ( q24h ) ( Cohort 1 ) 50 mg q12h ( Cohort 2 ) 7 day Period 2 ; metformin 500 mg q12h 10 day Period 3 . There washout period treatment . All dos study drug take follow meal . Safety evaluation collect period . Serial pharmacokinetic ( PK ) sample collect metformin last day period dolutegravir last day Period 2 .</brief_summary>
	<brief_title>Effect Dolutegravir Metformin Pharmacokinetics Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Male/females age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include [ medical history , physical examination , laboratory test cardiac monitoring ] . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( Kg ) males &gt; =45 Kg females body mass index ( BMI ) within range 18.5 31.0 Kg/m^2 ( square meter ) ( inclusive ) . A female subject eligible participate : nonchildbearing potential define premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international unit per milliliter ( MIU/mL ) estradiol &lt; 40 picograms ( pg ) /mL ( &lt; 147 picomole per liter ( pmol/L ) confirmatory ] ; Childbearing potential negative pregnancy test determine [ serum urine ] human chorionic gonadotropin ( hCG ) test screen prior dosing AND Agrees use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 5 day postlast dose . OR samesex partner , prefer usual lifestyle . Capable give write informed consent , include compliance requirement restriction list consent form Alanine aminotransferase , alkaline phosphatase bilirubin &lt; = 1.5x Upper Limit Normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A single repeat allow eligibility determination . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Pregnant female determine positive [ serum urine ] hCG test screen prior dosing . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GlaxoSmithKline ( GSK ) Medical Monitor , contraindicate participation . Subjects allergy tricyclic antidepressant enrol . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Lactating female . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Regular use tobacco nicotinecontaining product within 6 month prior screen . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St. John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . The subject 's systolic blood pressure outside range 90140 millimeter mercury ( mmHg ) , diastolic pressure outside range 4590 mmHg , heart rate outside range 50100 beat per minute ( bpm ) female subject 45100 bpm male subject . A single repeat allow eligibility determination . Exclusion criterion screen electrocardiogram ( ECG ) ( single repeat allow eligibility determination ) : Heart rate male &lt; 45 &gt; 110 bpm female &lt; 50 &gt; 100 bpm ; PR interval &lt; 120 &gt; 220 msec , QRS duration &lt; 70 &gt; 120 msec , QTc interval ( Bazett ) &gt; 450 msec . Evidence previous myocardial infarction ( Does include ST segment change associate repolarization ) ; clinically significant arrhythmia , opinion investigator GSK Medical Monitor , interfere safety individual subject ; conduction abnormality ( include specific leave right incomplete bundle branch block , atrioventricular block [ 2nd degree high ] , Wolf Parkinson White [ WPW ] syndrome ) , sinus pause &gt; 3 second , nonsustained sustain ventricular tachycardia ( &gt; =3 consecutive ventricular ectopic beat ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Dolutegravir</keyword>
	<keyword>drug interaction</keyword>
	<keyword>metformin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>